ECSP21012501A - Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas - Google Patents

Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas

Info

Publication number
ECSP21012501A
ECSP21012501A ECSENADI202112501A ECDI202112501A ECSP21012501A EC SP21012501 A ECSP21012501 A EC SP21012501A EC SENADI202112501 A ECSENADI202112501 A EC SENADI202112501A EC DI202112501 A ECDI202112501 A EC DI202112501A EC SP21012501 A ECSP21012501 A EC SP21012501A
Authority
EC
Ecuador
Prior art keywords
nash
treatment
nafld
combinations
related diseases
Prior art date
Application number
ECSENADI202112501A
Other languages
English (en)
Spanish (es)
Inventor
Trenton Thomas Ross
William Paul Esler
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP21012501A publication Critical patent/ECSP21012501A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
ECSENADI202112501A 2018-08-31 2021-02-23 Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas ECSP21012501A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862726172P 2018-08-31 2018-08-31
US201962883860P 2019-08-07 2019-08-07

Publications (1)

Publication Number Publication Date
ECSP21012501A true ECSP21012501A (es) 2021-03-31

Family

ID=68165623

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202112501A ECSP21012501A (es) 2018-08-31 2021-02-23 Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas

Country Status (23)

Country Link
US (2) US11254660B2 (enExample)
EP (1) EP3843740A1 (enExample)
JP (1) JP7161605B2 (enExample)
KR (1) KR102614808B1 (enExample)
CN (1) CN112955147A (enExample)
AU (1) AU2019329884B2 (enExample)
BR (1) BR112021003039A2 (enExample)
CA (1) CA3110601C (enExample)
CL (1) CL2021000491A1 (enExample)
CO (1) CO2021002230A2 (enExample)
CR (1) CR20210110A (enExample)
DO (1) DOP2021000036A (enExample)
EC (1) ECSP21012501A (enExample)
IL (1) IL281093B2 (enExample)
MA (1) MA53496A (enExample)
MX (1) MX2021002428A (enExample)
PH (1) PH12021550339A1 (enExample)
PY (1) PY1972032A (enExample)
SG (1) SG11202101503RA (enExample)
TW (1) TWI718644B (enExample)
UY (1) UY38351A (enExample)
WO (1) WO2020044266A1 (enExample)
ZA (1) ZA202101090B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11590161B2 (en) 2018-08-13 2023-02-28 Viscera Labs, Inc. Therapeutic composition and methods
EA202191432A1 (ru) 2018-11-22 2021-10-14 Цилу Регор Терапьютикс Инк. Агонисты glp-1r и их применения
WO2020142365A1 (en) * 2018-12-31 2020-07-09 Christos Mantzoros Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
BR112021013924A2 (pt) 2019-01-18 2021-09-21 Astrazeneca Ab Inibidores de pcsk9 e métodos de uso do mesmo
AU2020256647B2 (en) 2019-04-12 2025-07-31 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof
PT4097099T (pt) 2020-02-07 2024-07-19 Gasherbrum Bio Inc Agonistas heterocíclicos de glp-1
JP2022058085A (ja) * 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
JP2021134211A (ja) * 2020-02-24 2021-09-13 ファイザー・インク Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ
IL296100A (en) * 2020-03-11 2022-11-01 Dong A St Co Ltd A medicinal preparation for the prevention or treatment of non-alcoholic steatohepatitis
WO2021211959A2 (en) * 2020-04-18 2021-10-21 Inipharm, Inc. Methods and compositions for treating drug induced steatohepatitis
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
WO2021219019A1 (en) 2020-04-29 2021-11-04 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN117645601A (zh) * 2020-06-10 2024-03-05 重庆康丁医药技术有限公司 一种具有心血管益处的glp-1小分子
CN113816948B (zh) * 2020-06-19 2023-08-11 江苏恒瑞医药股份有限公司 稠合咪唑类衍生物、其制备方法及其在医药上的应用
PE20231181A1 (es) 2020-08-06 2023-08-11 Gasherbrum Bio Inc Agonistas del glp-1 heterociclicos
JP2023538408A (ja) * 2020-08-21 2023-09-07 ターンズ・ファーマシューティカルズ・インコーポレイテッド Ｇｌｐ－１ｒ作動薬としての化合物
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
CN112635049A (zh) * 2020-12-23 2021-04-09 无锡市第二人民医院 一种研究HSD17B13 rs72613567基因变异和肾功能损伤之间关系的方法
SI4408840T1 (sl) 2021-09-27 2025-12-31 Terns Pharmaceuticals, Inc. Benzimidazolne karboksilne kisline kot agonisti GLP-1R
US12024507B2 (en) 2021-10-25 2024-07-02 Terns Pharmaceuticals, Inc. Compounds as GLP-1R agonists
AU2023224854A1 (en) 2022-02-23 2024-10-03 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
EP4490155A1 (en) 2022-03-09 2025-01-15 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
US20250250269A1 (en) 2022-04-14 2025-08-07 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN121002014A (zh) 2022-12-15 2025-11-21 加舒布鲁姆生物公司 具有glp-1激动剂活性的化合物的盐和固体形式
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
EP4731212A1 (en) * 2023-06-20 2026-04-29 Sagimet Biosciences Inc. Combination therapies of fasn inhibitors with thyroid hormone receptor agonists
WO2025080818A1 (en) * 2023-10-10 2025-04-17 Sagimet Biosciences Inc. Combinations of fasn inhibitors and glp-1 agonists for liver diseases
CN118787746B (zh) * 2024-07-01 2025-09-16 安徽省立医院(中国科学技术大学附属第一医院) 脂肪酸合成酶抑制剂在预防及治疗药物性肝损伤中的应用
CN120698959B (zh) * 2025-05-29 2026-01-23 河北医科大学 一种达格列净-依折麦布共无定形物及其制备方法和应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
EP0028489B1 (en) 1979-11-05 1983-10-05 Beecham Group Plc Enzyme derivatives, and their preparation
DE3438830A1 (de) 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
ES2111065T5 (es) 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP3265680B2 (ja) 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
ID26984A (id) 1998-07-06 2001-02-22 Bristol Myers Squibb Co Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
CA2439152C (en) 2001-02-28 2008-06-17 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
WO2003072197A1 (en) 2002-02-27 2003-09-04 Pfizer Products Inc. Acc inhibitors
EA011086B9 (ru) 2004-05-12 2012-08-30 Пфайзер Продактс Инк. Производные пролина и их применение в качестве ингибиторов дипептидилпептидазы iv
GEP20094723B (en) 2004-05-25 2009-07-10 Pfizer Prod Inc Tetraazabenzo [e] azulene derivatives and analogs thereof
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
EP2010520B1 (en) 2006-04-20 2012-09-12 Pfizer Products Inc. Heterobicyclic amides for the prevention and treatment of glucokinase-mediated diseases
WO2008065508A1 (en) 2006-11-29 2008-06-05 Pfizer Products Inc. Spiroketone acetyl-coa carboxylase inhibitors
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
EP2297164A1 (en) 2008-05-28 2011-03-23 Pfizer Inc. Pyrazolospiroketone acetyl-coa carboxylase inhibitors
JP5435592B2 (ja) 2008-05-28 2014-03-05 ファイザー・インク ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤
CA2729581A1 (en) 2008-07-29 2010-02-04 Pfizer Inc. Fluorinated heteroaryls
ES2380408T3 (es) 2008-08-28 2012-05-11 Pfizer Inc. Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
TW201038580A (en) 2009-02-02 2010-11-01 Pfizer 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
WO2010103437A1 (en) 2009-03-11 2010-09-16 Pfizer Inc. Benzofuranyl derivatives used as glucokinase inhibitors
EP2406230A1 (en) 2009-03-11 2012-01-18 Pfizer Inc. Substituted indazole amides and their use as glucokinase activators
CA2754523A1 (en) 2009-03-20 2010-09-23 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
EP2427448A1 (en) 2009-05-08 2012-03-14 Pfizer Inc. Gpr 119 modulators
CA2759843A1 (en) 2009-05-08 2010-11-10 Pfizer Inc. Gpr 119 modulators
GEP20135907B (en) 2009-06-05 2013-08-12 Pfizer L-(piperidin-4-yl)-pyrazole derivatives as gpr 119 modulators
WO2011005611A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Neuromedin u receptor agonists and uses thereof
CH702192A1 (de) 2009-11-04 2011-05-13 New Dent Ag Keramisches Implantat.
DK2621493T3 (en) * 2010-09-30 2016-10-24 Pfizer N1 PYRAZOLOSPIROKETON-ACETYL-CoA carboxylase INHIBITORS
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
MX2017008844A (es) 2015-01-09 2018-03-14 Gilead Apollo Llc Terapia de combinacion con inhibidor de acetil-coa carboxilasa (acc) para el tratamiento de enfermedad de higado graso no alcoholico.
TN2018000198A1 (en) 2015-12-29 2019-10-04 Pfizer Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
AR109179A1 (es) * 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
CN106271089B (zh) 2016-09-30 2019-01-25 英诺激光科技股份有限公司 一种激光薄膜刻蚀装置及方法
WO2018109607A1 (en) 2016-12-16 2018-06-21 Pfizer Inc. Glp-1 receptor agonists and uses thereof
EP3713942B8 (en) 2017-11-21 2023-04-12 Pfizer Inc. Crystalline 2-amino-2-(hydroxymethyl)propane-1,3-diol salt of 4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6-methoxypyridin-2-yl)benzoic acid

Also Published As

Publication number Publication date
CR20210110A (es) 2021-05-13
CO2021002230A2 (es) 2021-03-08
PH12021550339A1 (en) 2021-10-04
AU2019329884B2 (en) 2022-01-27
US11254660B2 (en) 2022-02-22
PY1972032A (es) 2021-06-03
JP2021535126A (ja) 2021-12-16
CL2021000491A1 (es) 2021-08-20
TW202026292A (zh) 2020-07-16
ZA202101090B (en) 2022-06-29
TWI718644B (zh) 2021-02-11
MX2021002428A (es) 2023-01-02
CA3110601C (en) 2023-09-05
JP7161605B2 (ja) 2022-10-26
MA53496A (fr) 2021-12-08
KR20210053929A (ko) 2021-05-12
US20220023299A1 (en) 2022-01-27
US12247022B2 (en) 2025-03-11
UY38351A (es) 2020-03-31
KR102614808B1 (ko) 2023-12-19
DOP2021000036A (es) 2021-04-15
EP3843740A1 (en) 2021-07-07
IL281093A (en) 2021-04-29
US20200071306A1 (en) 2020-03-05
IL281093B2 (en) 2025-11-01
IL281093B1 (en) 2025-07-01
SG11202101503RA (en) 2021-03-30
CN112955147A (zh) 2021-06-11
CA3110601A1 (en) 2020-03-05
WO2020044266A1 (en) 2020-03-05
AU2019329884A1 (en) 2021-03-11
BR112021003039A2 (pt) 2021-05-18

Similar Documents

Publication Publication Date Title
CL2021000491A1 (es) Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas
ECSP20013248A (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
BR112016023269A8 (pt) uso de ácido (r)-2-(4-((2-etóxi-3-(4-(trifluormetil)fenóxi)propil)-tio)-2-metilfenóxi)-acético ou sal do mesmo na fabricação de um medicamento para tratar doença hepática gordurosa não alcoólica ou esteato-hepatite não alcoólica
AR112284A1 (es) Combinación que comprende palbociclib y ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxílico
MX2017010287A (es) Composiciones farmaceuticas que comprenden n-(3,5-dimetoxifenil)-n '-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il)quinoxalin-6-il]eta no-1,2-diamina.
RU2017105353A (ru) Соединения
MX2016014634A (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
ECSP088473A (es) FORMAS DE CRISTAL F, G, H, I, y K DEL MESILATO DE IMATINIB
UY31125A1 (es) Formas amorfas estabilizadas de mesilato de imatinib
AR100663A1 (es) Formulaciones de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona
MX2014002471A (es) Combinaciones sinergicas de los inhibidores de p13k y mek.
MX2015017629A (es) Combinaciones farmaceuticas.
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
WO2018005801A3 (en) Novel non-systemic tgr5 agonists
MX2021014161A (es) Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton.
AR119159A1 (es) Tratamientos de angioedema
ECSP21003707A (es) Forma de dosificación farmacéutica administrable por vía oral con liberación modificada
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
EA202190544A1 (ru) Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний
CL2020003162A1 (es) Método de administración de una cantidad terapéuticamente efectiva de 5-[[4-[2-[5-(1- hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidina-2,4-diona
CO6260065A2 (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta para la preparacion de un medicamento para regular el nivel de potasio en la sangre
AR117614A1 (es) Forma de dosificación farmacéutica administrable por vía oral con liberación modificada
RU2019111873A (ru) Новые антимикробные соединения, их применение для лечения инфекций млекопитающих и новый метаболический механизм
NZ708802A (en) Pharmaceutical combinations comprising a protein kinase c inhibitor compound and a mitogen activated protein kinase inhibitor compound
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.